173 related articles for article (PubMed ID: 33028256)
1. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
[TBL] [Abstract][Full Text] [Related]
2. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
3. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Noble SM; Garfield K; Lane JA; Metcalfe C; Davis M; Walsh EI; Martin RM; Turner EL; Peters TJ; Thorn JC; Mason M; Bollina P; Catto JWF; Doherty A; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Rosario DJ; Rowe E; Oxley J; Staffurth J; Neal DE; Hamdy FC; Donovan JL
Br J Cancer; 2020 Sep; 123(7):1063-1070. PubMed ID: 32669672
[TBL] [Abstract][Full Text] [Related]
4. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
5. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.
Ramsay C; Pickard R; Robertson C; Close A; Vale L; Armstrong N; Barocas DA; Eden CG; Fraser C; Gurung T; Jenkinson D; Jia X; Lam TB; Mowatt G; Neal DE; Robinson MC; Royle J; Rushton SP; Sharma P; Shirley MD; Soomro N
Health Technol Assess; 2012; 16(41):1-313. PubMed ID: 23127367
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
8. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
[TBL] [Abstract][Full Text] [Related]
9. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials.
Glazener C; Boachie C; Buckley B; Cochran C; Dorey G; Grant A; Hagen S; Kilonzo M; McDonald A; McPherson G; Moore K; N'Dow J; Norrie J; Ramsay C; Vale L
Health Technol Assess; 2011 Jun; 15(24):1-290, iii-iv. PubMed ID: 21640056
[TBL] [Abstract][Full Text] [Related]
11. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1415-1424. PubMed ID: 27626136
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
13. Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service.
Close A; Robertson C; Rushton S; Shirley M; Vale L; Ramsay C; Pickard R
Eur Urol; 2013 Sep; 64(3):361-9. PubMed ID: 23498062
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
[TBL] [Abstract][Full Text] [Related]
15. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
Hamdy FC; Elliott D; le Conte S; Davies LC; Burns RM; Thomson C; Gray R; Wolstenholme J; Donovan JL; Fitzpatrick R; Verrill C; Gleeson F; Singh S; Rosario D; Catto JW; Brewster S; Dudderidge T; Hindley R; Emara A; Sooriakumaran P; Ahmed HU; Leslie TA
Health Technol Assess; 2018 Sep; 22(52):1-96. PubMed ID: 30264692
[TBL] [Abstract][Full Text] [Related]
16. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
[TBL] [Abstract][Full Text] [Related]
18. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.
Koerber F; Waidelich R; Stollenwerk B; Rogowski W
BMC Health Serv Res; 2014 Apr; 14():163. PubMed ID: 24721557
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Donovan JL; Hamdy FC; Lane JA; Mason M; Metcalfe C; Walsh E; Blazeby JM; Peters TJ; Holding P; Bonnington S; Lennon T; Bradshaw L; Cooper D; Herbert P; Howson J; Jones A; Lyons N; Salter E; Thompson P; Tidball S; Blaikie J; Gray C; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Davis M; Turner EL; Martin RM; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1425-1437. PubMed ID: 27626365
[TBL] [Abstract][Full Text] [Related]
20. Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.
Degeling K; Corcoran NM; Pereira-Salgado A; Hamid AA; Siva S; IJzerman MJ
Value Health; 2021 Dec; 24(12):1737-1745. PubMed ID: 34838271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
